Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Parsabiv (etelcalcetide by Year
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Rest of World (ROW) product sales ($M) ($M)
Amgen Parsabiv (etelcalcetide: $161M in FY2025, up 5.2% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Parsabiv— ROW | 161 | 5 | % | 153 | 14 | % | 134”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 161 | +5.2% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 153 | +14.2% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 134 | +3.9% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 129 | -0.8% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 130 | +17.1% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 111 | +38.7% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 80 | +135.3% | Form 10-K (amgn-12312019x10kq42019.htm, filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 34 | +580.0% | Form 10-K (amgn-12312018x10kq42018.htm, filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 5 | – | Form 10-K (amgn-12312018x10kq42018.htm, filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Parsabiv (etelcalcetide ($M), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-parsabiv-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.